Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Thursday morning. The brokerage issued a sell rating on the stock.

A number of other analysts have also issued reports on the stock. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $1.76 on Thursday. The company has a market capitalization of $6.23 million, a price-to-earnings ratio of -0.98 and a beta of 1.33. The firm has a 50-day moving average price of $1.57 and a 200 day moving average price of $1.95. Can-Fite BioPharma has a twelve month low of $1.29 and a twelve month high of $4.69.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets purchased a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.